Global lung oncology branch trial 3 (GLOB3): Final results of a randomised multinational phase III study alternating oral and i.v. vinorelbine plus cisplatin versus docetaxel plus cisplatin as first-line treatment of advanced non-small-cell lung cancer

Annals of Oncology

Volumn 20, Issue 7, 2009, Pages 1249-1256

  Tan, E H ^a   Rolski, J ^b   Grodzki, T ^c   Schneider, C P ^d   Gatzemeier, U ^e   Zatloukal, P ^f   Aitini, E ^g   Carteni, G ^h   Riska, H ⁱ   Tsai, Y H ^j   Abratt, R ^k  

^a DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^b INSTITUTE OF ONCOLOGY   (Poland)

^c Regional Hospital for Lung Diseases   (Poland)

^d Central Hospital Bad Berka   (Germany)

^e KRANKENHAUS GROSSHANSDORF   (Germany)

^f CHARLES UNIVERSITY   (Czech Republic)

^g CARLO POMA HOSPITAL   (Italy)

^h CARDARELLI HOSPITAL   (Italy)

ⁱ HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^j CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^k UNIVERSITY OF CAPE TOWN   (South Africa)

more..

Author keywords

Advanced NSCLC; Chemotherapy; Navelbine oral; Phase trial study; Platinum based

Indexed keywords

CISPLATIN; DEXAMETHASONE; DOCETAXEL; NAVELBINE; SEROTONIN 3 ANTAGONIST;

ABDOMINAL PAIN; ADENOCARCINOMA; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERANCE; DYSGEUSIA; DYSPEPSIA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FLUID RETENTION; HEMOGLOBIN BLOOD LEVEL; HUMAN; INJECTION SITE REACTION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PARESTHESIA; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SENSORY NEUROPATHY; SIDE EFFECT; SQUAMOUS CELL CARCINOMA; STOMATITIS; SURVIVAL RATE; THROMBOCYTOPENIA; TINNITUS; TREATMENT FAILURE; TREATMENT RESPONSE; VOMITING; WEIGHT REDUCTION;

ADMINISTRATION, ORAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; KAPLAN-MEIERS ESTIMATE; LUNG NEOPLASMS; MALE; PROSPECTIVE STUDIES; QUALITY OF LIFE; SURVIVAL ANALYSIS; TAXOIDS; TREATMENT OUTCOME; VINBLASTINE;

EID: 67650385658     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn774     Document Type: Article

References (33)

1. Bosetti C, Bertuccio P, Levi F et al. Cancer mortality in the European Union, 1970-2003, with a joinpoint analysis. Ann Oncol 2008; 19(4): 631-640.
2. Bunn PA Jr. Chemotherapy for advanced non-small-cell lung cancer: Who, what, when, why? J Clin Oncol 2002; 20: 23S-33S.
3. Hotta K, Matsuo K, Ueoka et al. Addition of platinum compounds to a new agent in patients with advanced non-small-cell lung cancer: A literature based meta-analysis of randomised trials. Ann Oncol 2004; 15: 1782-1789.
4. Fossella F, Pereira JR, von Pawel J et al. Randomised, multinational phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: The TAX 326 study group. J Clin Oncol 2003; 21: 3016-3024.
5. Schiller JH, Harrington D, Belani CP et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346: 92-98.
6. Souquet PJ, Tan EH, Rodrigues Pereira J et al. GLOB-1: Prospective randomised clinical phase III trial comparing vinorelbine-cisplatin with vinorelbine - ifosfamide - cisplatin in metastatic non-small-cell lung cancer patients. Ann Oncol 2002; 13: 1853-1861.
7. Gridelli C, Gallo C, Sheperd F et al. Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: A phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2003; 21: 3025-3034.
8. O'Neill VJ, Twelves CJ. Oral cancer treatment: Developments in chemotherapy and beyond. Br J Cancer 2002; 87: 933-937.
9. Liu G, Franssen E, Fitch MI et al. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997; 15: 110-115.
10. Jassem J, Ramlau R, Karnicka-Mlodkowska H et al. A multicenter randomized phase II study of oral vs intravenous vinorelbine in advanced non-small cell lung cancer patients. Ann Oncol 2001; 12: 1375-1381.
11. De Lena M, Ramlau R, Hansen O et al. Phase II trial of oral vinorelbine in combination with cisplatin followed by consolidation therapy with oral vinorelbine in advanced NSCLC. Lung Cancer 2005; 48: 129-135.
12. Wozniak AJ, Crowley JJ, Balcerzak SP et al. Randomized trial comparing cisplatin with cisplatin versus cisplatin plus vinorelbine in the treatment of advanced non-small cell lung cancer: A southwest oncology group study. J Clin Oncol 1998; 16: 2459-2465.
13. Kelly K, Crowley J, Bunn PA et al. A randomized phase III trial of paclitaxel plus carboplatin (PC) versus vinorelbine plus cisplatin (VC) in untreated advanced non-small cell lung cancer (NSCLC): A Southwest Oncology Group (SWOG) trial. J Clin Oncol 2001; 19: 3210-3218.
14. Gebbia V, Galetta D, Lorusso V et al. Cisplatin plus weekly vinorelbine versus cisplatin plus vinorelbine on days 1 and 8 in advanced NSCLC: A prospective randomized phase III trial of the G.O.I.M. Lung Cancer 2008; 61: 369-377.
15. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92(3): 205-216.
16. Hollen PJ, Gralla RJ, Kris MG. An Overview of the Lung Cancer Symptom Scale. 1995 [Monograph, pp. 57-63]. Quality of Life. Symposium, 7th World Conference on Lung Cancer, Colorado Springs, CO, 1994.
17. Scagliotti GV, Parikh P, von Pawel J et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008; 26: 3543-3551.
18. Yabroff KR, Warren JL, Knopf K et al. Estimating patient time cost associated with colorectal cancer care. Med Care 2005; 43: 640-648.
19. Findlay M. Effective oral chemotherapy for breast cancer: Pillars of strength. Ann Oncol 2008; 19: 212-222.
20. Kuppens IE, Breedveld P, Beijnen JH et al. Modulation of oral drug bioavailability: From preclinical mechanism to therapeutic application. Cancer Invest 2005; 23: 443-464.
21. Blanchette J, Peppas NA. Oral chemotherapeutic delivery: Design and cellular response. Ann Biomed Eng 2005; 33: 142-149.
22. Wojtacki J, Wiraszka R, Rolka-Stempniewicz G et al. Breast cancer patients' preferences for oral versus intravenous second-line anticancer therapy. Eur J Cancer 2006; 4 (Suppl 2): 159 (Abstr 381).
23. Fallowfield L, Atkins L, Catt S et al. Patients' preference for administration of endocrine treatments by injection or tablets: Results from a study of women with breast cancer. Ann Oncol 2006; 17: 205-210.
24. Paley M, Love N, Carlson R et al. Preferences for oral and parental antitumor therapy: A survey of 260 patients with metastatic breast cancer. Proc Am Soc Clin Oncol 2005; 23(16S): 619.
25. Jensen L, Osterlind K, Rytter C. Randomized cross-over study of patient preference for oral or intravenous vinorelbine in combination with carboplatin in the treatment of advanced NSCLC. Lung Cancer 2008; 62: 85-91.
26. Partridge AH, Avorn J, Wang PS et al. Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst 2002; 94: 652-661.
27. Sharma S. Patient selection for oral chemotherapy. Oncology 2001; 15 (1 Suppl 2): 33-35.
28. Damle B, Ravandi F, Kaul S et al. Effect of food on the oral bioavailability of UFT and leucovorin in cancer patients. Clin Cancer Res 2001; 7: 517-523.
29. Faithfull S, Deery P. Implementation of capecitabien (Xeloda) into a cancer centre: UK experience. Eur J Oncol Nurs 2004; 8 (Suppl 1): S54-S62.
30. Chau I, Legge S, Fumeleau P. The vital role of education and information in patients receiving capectabine (Xeloda). Eur J Oncol Nurs 2004; 8 (Suppl 1): S41-S53.
31. Douillard JY, Fossella F, Georgiulias V et al. Comparison of docetaxel and vinca-alkaloid, alone or in combination with other chemotherapy agents, in the first line treatment of advanced non-small cell lung cancer (NSCLC): A meta-analysis. Proc Am Soc Clin Oncol 2006; 24: (Abstr 7034).
32. Meert AP, Sculier JP. What has the meta-analysis contributed to today's standard of care in the treatment of thoracic malignancies? Lung Cancer 2008; 61: 141-151.
33. Pirker R, Szczesna A, Von Pawel J et al. Randomized, multicenter, phase III study of cetuximab in combination with cisplatin/vinorelbine vs CV alone in the first - line treatment of patients with advanced NCLC. J Clin Oncol 2008; 26(18S) (Suppl): 1006S.